Mirtastad (Mirtazapine)

Mirtazapine works by blocking presynaptic alpha‑2 adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonizes specific serotonin (5‑HT2, 5‑HT3) and histamine (H1) receptors, enhancing mood and providing a sedative effect.

The appropriate dose of Mirtastad is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions exactly.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtastad (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of alpha‑2 adrenergic and specific serotonin receptors. This mechanism often results in a distinct side‑effect profile, including higher rates of sedation and weight gain, which may be advantageous for patients with insomnia or appetite loss.

Mirtastad tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mirtastad is taken orally as a tablet, usually once daily in the evening. The tablet should be swallowed whole with water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hypersensitivity reactions, seizures, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Patients should be monitored closely for any signs of these conditions.

Mirtastad is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs). Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiovascular disease, or a history of seizures.